Skip to main content
. 2023 Feb 21;24(5):4272. doi: 10.3390/ijms24054272

Figure 1.

Figure 1

Identification of differentially expressed miRs in hepatocellular carcinoma (HCC) cancer-associated fibroblasts (CAFs). (a) Isolation of CAFs, para-cancer fibroblasts (PAFs), and normal fibroblasts (NFs) from surgically resected liver tissues. (b) Flow chart of this study’s protocol for selecting CAF-derived miRs in HCC. (c) Expression of upregulated (right panel) and downregulated (left panel) miRs in CAFs compared to NFs and PAFs. (d) Heatmaps of differentially expressed miRs. Left: heatmap of the 17 downregulated miRs; right: heatmap of the 14 upregulated miRs. (e) Venn diagram of differently expressed miRs in CAFs and in TCGA_LIHC. (f) Comparison of expression of hsa-miR-101-3p, hsa-miR-490-3p, and hsa-miR-95-3p in CAFs compared to PAFs (left) and in HCC tissue compared to non-tumor tissue in TCGA_LIHC (right). (g) Clinical-stage analysis of hsa-miR-101-3p, hsa-miR-490-3p, and hsa-miR-95-3p in Catholic_LIHC. Expression of the miRs in normal cases, chronic hepatitis, liver cirrhosis, dysplastic nodule, early HCC, and advanced HCC. (h) Clinical-stage analysis of hsa-miR-101-3p, hsa-miR-490-3p, and hsa-miR-95-3p in Tsinghua_LIHC. Expression of the miRs in normal tissues, tumor tissues without portal vein tumor thrombosis, and tumor tissues with portal vein tumor thrombosis. * p < 0.05; ** p < 0.01; *** p < 0.001.